1
|
De Mel S, Goh J, Rashid MBMA, Zhang XY, Jaynes P, Liu X, Poon L, Chan E, Lee J, Chee YL, Koh LP, Tan LK, Soh TG, Yuen YC, Loi H, Ng S, Goh X, Tan D, Cheah DMZ, Pang WL, Huang D, Chan JY, Somasundaram N, Tang T, Lim ST, Ong CK, Chng W, Chow EK, Jeyasekharan AD. CLINICAL APPLICATION OF AN EX‐VIVO PLATFORM TO GUIDE THE CHOICE OF DRUG COMBINATIONS IN RELAPSED/REFRACTORY LYMPHOMA; A PROSPECTIVE STUDY. Hematol Oncol 2021. [DOI: 10.1002/hon.147_2880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- S De Mel
- National University Health System Department of Haematology‐Oncology National University Cancer Institute, Singapore Singapore Singapore
| | - J Goh
- National University of Singapore Cancer Science Institute of Singapore Singapore Singapore
| | | | - X. Y Zhang
- National University of Singapore Cancer Science Institute of Singapore Singapore Singapore
| | - P Jaynes
- National University of Singapore Cancer Science Institute of Singapore Singapore Singapore
| | - X Liu
- National University Health System Department of Haematology‐Oncology National University Cancer Institute, Singapore Singapore Singapore
| | - L Poon
- National University Health System Department of Haematology‐Oncology National University Cancer Institute, Singapore Singapore Singapore
| | - E Chan
- National University Health System Department of Haematology‐Oncology National University Cancer Institute, Singapore Singapore Singapore
| | - J Lee
- National University Health System Department of Haematology‐Oncology National University Cancer Institute, Singapore Singapore Singapore
| | - Y. L Chee
- National University Health System Department of Haematology‐Oncology National University Cancer Institute, Singapore Singapore Singapore
| | - L. P Koh
- National University Health System Department of Haematology‐Oncology National University Cancer Institute, Singapore Singapore Singapore
| | - L. K Tan
- National University Hospital Department of Laboratory Medicine Singapore Singapore
| | - T. G Soh
- National University Hospital Department of Laboratory Medicine Singapore Singapore
| | - Y. C Yuen
- National University Health System Department of Pharmacy Singapore Singapore
| | - Hoi‐Y Loi
- National University Hospital Singapore Department of Diagnostic Imaging Singapore Singapore
| | - Siok‐B Ng
- National University of Singapore Department of Pathology Yong Loo Lin School of Medicine Singapore Singapore
| | - X Goh
- National University Hospital, Department of Otorhinolaryngology Singapore Singapore
| | - D Tan
- Mt Elizabeth Hospital, Dr Daryl Tan Clinic for Lymphoma, Myeloma and Blood Disorders Singapore Singapore
| | - D. M. Z Cheah
- National Cancer Centre Singapore Lymphoma Genomic Translational Research Laboratory Division of Cellular and Molecular Research Singapore Singapore
| | - W. L Pang
- National Cancer Centre Singapore Lymphoma Genomic Translational Research Laboratory Division of Cellular and Molecular Research Singapore Singapore
| | - D Huang
- National Cancer Centre Singapore Lymphoma Genomic Translational Research Laboratory Division of Cellular and Molecular Research Singapore Singapore
| | - J. Y Chan
- National Cancer Centre Singapore Division of Medical Oncology Singapore Singapore
| | - N Somasundaram
- National Cancer Centre Singapore Division of Medical Oncology Singapore Singapore
| | - T Tang
- National Cancer Centre Singapore Division of Medical Oncology Singapore Singapore
| | - S. T Lim
- National Cancer Centre Singapore Division of Medical Oncology Singapore Singapore
| | - C. K Ong
- National Cancer Centre Singapore Division of Cellular and Molecular Research Singapore Singapore
| | - W.‐J Chng
- National University Health System Department of Haematology‐Oncology National University Cancer Institute, Singapore Singapore Singapore
| | - E. K Chow
- National University of Singapore Cancer Science Institute of Singapore Singapore Singapore
| | - A. D Jeyasekharan
- National University Health System Department of Haematology‐Oncology National University Cancer Institute, Singapore Singapore Singapore
| |
Collapse
|
2
|
Lim J, Huang D, Tang T, Cai Q, Tan D, Laurensia Y, Chia B, Rou-Jun P, Pang W, Cheah D, Ng C, Hong H, Tan J, Feng L, Chen J, Han B, Guo Y, Goh Y, Rötzschke O, Cheng C, Au-Yeung R, Chan T, Ng S, Kwong Y, Hwang W, Chng W, Tousseyn T, Tan P, Teh B, Khor C, Rozen S, Bei J, Lin T, Lim S, Ong C. WHOLE-GENOME SEQUENCING REVEALS IMMUNOTHERAPEUTIC OPTIONS FOR NATURAL-KILLER/T CELL LYMPHOMA PATIENTS. Hematol Oncol 2019. [DOI: 10.1002/hon.19_2630] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
3
|
Teoh P, An O, Chung T, Chooi J, Toh S, Fan S, Wang W, Koh B, Fullwood M, Ooi M, de Mel S, Soekojo C, Chen P, Ng S, Yang H, Chng W. ABERRANT HYPEREDITING OF MYELOMA TRANSCRIPTOME BY ADAR1 CONFERS ONCOGENICITY AND IS A MARKER OF POOR PROGNOSIS. Hematol Oncol 2019. [DOI: 10.1002/hon.237_2631] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- P. Teoh
- Cancer Science Institute of Singapore; National University of Singapore; Singapore Singapore
| | - O. An
- Cancer Science Institute of Singapore; National University of Singapore; Singapore Singapore
| | - T. Chung
- Cancer Science Institute of Singapore; National University of Singapore; Singapore Singapore
| | - J. Chooi
- Cancer Science Institute of Singapore; National University of Singapore; Singapore Singapore
| | - S. Toh
- Cancer Science Institute of Singapore; National University of Singapore; Singapore Singapore
| | - S. Fan
- Pathology; National University of Singapore; Singapore Singapore
| | - W. Wang
- Orthopaedic; National University Hospital; Singapore Singapore
| | - B. Koh
- Orthopaedic; National University Hospital; Singapore Singapore
| | - M. Fullwood
- Cancer Science Institute of Singapore; National University of Singapore; Singapore Singapore
| | - M. Ooi
- National University Cancer Institute; National University Hospital; Singapore Singapore
| | - S. de Mel
- National University Cancer Institute; National University Hospital; Singapore Singapore
| | - C. Soekojo
- National University Cancer Institute; National University Hospital; Singapore Singapore
| | - P. Chen
- Cancer Science Institute of Singapore; National University of Singapore; Singapore Singapore
| | - S. Ng
- Pathology; National University of Singapore; Singapore Singapore
| | - H. Yang
- Cancer Science Institute of Singapore; National University of Singapore; Singapore Singapore
| | - W. Chng
- National University Cancer Institute; National University Hospital; Singapore Singapore
| |
Collapse
|
4
|
Tuchman SA, Chng W, Anguiano A, Barry WT, Zhan F, Gasparetto C, Fonseca R, Shaughnessy JD, Potti A. The multi-institutional myeloma group clinico-genomic risk stratification system: A blinded validation. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.8521] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
8521 Background: Several clinical and molecular prognostic factors (e.g, International Staging System [ISS] stage, plasma cell labeling index, genomic models) exist for multiple myeloma (MM). We hypothesized that exploiting gene signatures representative of oncogenic pathway deregulation (i.e., Ras, Myc, etc.), would improve MM prognostication and also aid with the identification of novel therapeutic targets. Methods: Using a discovery cohort (n=47) of patients with MM and corresponding gene expression data, we built upon current molecular risk-stratification and devised a Bayesian genomic (“metagene”) model for prognosis. We validated that model in an independent patient cohort (n=207). Finally, we incorporated ISS staging and clinical variables to construct a combined Clinico-Genomic Risk Stratification System. We further validated the combined model in a separate cohort (n=72), in a blinded manner. Results: Using gene signatures predictive of oncogenic pathway activation in the discovery cohort, we identified specific patterns (metagenes) of signaling pathway activation with prognostic relevance. In an independent validation cohort, this metagene-based model accurately predicted event free survival (EFS) independently of ISS (multivariate hazard ratio [HR] 3.4 for ISS stage, and 5.4 for the metagene model, p=0.002). Using multivariate risk modeling, we incorporated ISS staging and the metagene model into a Clinico-Genomic System and successfully stratified the validation cohort into three groups (low, intermediate, and high risk) with markedly different EFS (HR 4.2 for intermediate risk and 14.0 for high risk vs. the low risk cohort, p<0.0001). In an additional blinded validation, the Clinico-Genomic System again accurately predicted median overall survival (68.7 [low risk] vs 24.7 [intermediate risk] vs 18.7 months [high risk], p<0.0001); more accurately than either ISS or other reported genomic models. Conclusions: A combined Clinico-Genomic Risk Stratification System, building on patterns of oncogenic pathway activation and ISS staging system, improves upon current prognostic models in MM and identifies novel pathway targets for future therapeutic consideration. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- S. A. Tuchman
- Duke University, Durham, NC; Mayo Clinic, Scottsdale, AZ; University of Utah, Salt Lake City, UT; University of Arkansas, Little Rock, AR
| | - W. Chng
- Duke University, Durham, NC; Mayo Clinic, Scottsdale, AZ; University of Utah, Salt Lake City, UT; University of Arkansas, Little Rock, AR
| | - A. Anguiano
- Duke University, Durham, NC; Mayo Clinic, Scottsdale, AZ; University of Utah, Salt Lake City, UT; University of Arkansas, Little Rock, AR
| | - W. T. Barry
- Duke University, Durham, NC; Mayo Clinic, Scottsdale, AZ; University of Utah, Salt Lake City, UT; University of Arkansas, Little Rock, AR
| | - F. Zhan
- Duke University, Durham, NC; Mayo Clinic, Scottsdale, AZ; University of Utah, Salt Lake City, UT; University of Arkansas, Little Rock, AR
| | - C. Gasparetto
- Duke University, Durham, NC; Mayo Clinic, Scottsdale, AZ; University of Utah, Salt Lake City, UT; University of Arkansas, Little Rock, AR
| | - R. Fonseca
- Duke University, Durham, NC; Mayo Clinic, Scottsdale, AZ; University of Utah, Salt Lake City, UT; University of Arkansas, Little Rock, AR
| | - J. D. Shaughnessy
- Duke University, Durham, NC; Mayo Clinic, Scottsdale, AZ; University of Utah, Salt Lake City, UT; University of Arkansas, Little Rock, AR
| | - A. Potti
- Duke University, Durham, NC; Mayo Clinic, Scottsdale, AZ; University of Utah, Salt Lake City, UT; University of Arkansas, Little Rock, AR
| |
Collapse
|